MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
May 10, 2022
Apr 27, 2022
Mar 18, 2022
MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Data provided by Kaleidoscope.
Events and Presentations
January 27, 2022 at 12:00 PM EST
December 1, 2021 at 8:25 AM EST
November 10 - November 14, 2021